Skip secondary menu

Neuroimmunological Diseases Unit - Division of Intramural Research


Bielekova, B.
Daclizumab therapy for multiple sclerosis, Neurotherapeutics, 2013, vol. 10(1), pp. 55-67.


Bielekova, B., Komori, M., Xu, Q., Reich, D.S. and Wu, T
Cerebrospinal fluid IL-12p40, CXCL13 and IL-8 as a combinatorial biomarker of active intrathecal inflammation, PLoS One, 2012, vol. 7(11), pp. e48370.

Perry, J.S., Han, S., Xu, Q., Herman, M.L., Kennedy, L.B., Csako, G. and Bielekova, B.
Inhibition of LTi cell development by CD25 blockade is associated with decreased intrathecal inflammation in multiple sclerosis, Science Translational Medicine, 2012, vol. 4(145), pp. 145ra106.


Bielekova B., Richert, N., Herman, M.L., Ohayon, J., Waldmann, T.A., McFarland, H., Martin, R. and Blevins, G.
Intrathecal effects of daclizumab treatment of multiple sclerosis, Neurology, 2011, vol. 77(21), pp. 1877-1886.

Wuest, S., Edwan, J., Martin, J., Han, S., Perry, J., Cartagena, C., Matsuura, E., Maric, D., Waldmann, T.A., and Bielekova, B.
A vital role for IL-2 trans-presentation in DC-mediated T cell activation as revealed by daclizumab therapy, Nature Medicine, 2011, vol. May; 17(5), pp. 604-609.

Jiang, W., Chai, N. R., Maric, D. and Bielekova, B.
Unexpected role for granzyme K in CD56bright NK cell-mediated immunoregulation of multiple sclerosis, Journal of Immunology (Jun 10, Epub ahead of print), 2011


Bielekova, B. and Becker, B.L
Monoclonal antibodies in MS: mechanisms of action, Neurology, 2010, vol. 74 (Suppl 1), pp. S31-S40.

Martin, M., Perry, J., Jakhete, N., Wang, X and Bielekova, B.
An IL-2 paradox: Blocking CD25 on T Cells Induces IL-2-driveb Activation of CD56bright NK cells, Journal of Immunology, 2010, vol. 185(2), pp. 1311-1320.


Bielekova, B., Howard, T., Packer, A., Richert, N., Blevins, G., Ohayon, J., Waldmann, T. A., McFarland, H. And Martin, R.
The anti-CD25 Antibody Daclizumab Inhibits Inflammation and Stabilizes Disease Progression in MS, Archives of Neurology, 2009, vol. 66(4), pp. 483-489.


Muraro, P. and Bielekova, B.
Emerging therapies for MS, Neurotherapeutics, 2007, vol. 4 (4), pp. 676-692.


Bielekova B, Catalfamo M, Reichert-Scrivner S, Packer A, Cerna M, Waldmann TA, McFarland H, Henkart PA, Martin R.
Regulatory CD56bright natural killer cells mediate immunomodulatory effects of IL-2Ra-targeted therapy (daclizumab) in multiple sclerosis, Proceedings of the National Academy of Sciences, USA, 2006, vol. 103: 15, pp. 5941-5946.


Bielekova, B., Kadom, N., Jeffries, Fisher, E., Howard, T., Ohayon, J., N., Richert, N., Bash, C. N., Frank, J., Stone, L., Martin, R., Cutter, G. and McFarland, H.
MRI as a Marker for Disease Heterogeneity in MS, Neurology, 2005, vol. 65 (7), pp. 1071-1076.


Bielekova, B., Howard, T., Blevins, G., Richert, N., Markovic-Plese, S., Scrivner-Reichert, S., Wurfel, J., Waldmann, T. A., McFarland, H. and Martin, R.
Humanized Anti-CD25 (Daclizumab) Inhibits Disease Activity in Multiple Sclerosis Patients Failing to Respond to Interferon-beta, Proceedings of the National Academy of Sciences,USA, 2004, vol. 10: 23, pp. 8705-8708.

Bielekova, B., Sung, M-H., Kadon, N., Simon, R., McFarland, H. and Martin, R.
Expansion and Functional Relevance of High-Avidity Myelin Specific T Cells in Multiple Sclerosis, Journal of Immunology, 2004, vol. 172, pp. 3893-3904.


Bielekova, B. and Martin, R.
Antigen-specific immunomodulation via altered peptide ligands, Journal of Molecular Medicine, 2001, vol. 79, pp. 552-565.


Bielekova, B., Goodwin, B., Richert, N., Cortese, I., Kondo, T., Afshar, G., Gran, B., Eaton, J., Antel, J., Frank, J., McFarland, H. and Martin, R.
Encephalitogenic Potential of Myelin Basic Protein Peptide (83-99) in Multiple Sclerosis - Results of a phase II clinical trial with an altered peptide ligand, Nature Medicine, 2000, vol. 6(10), pp. 1167-1175.

Back to Lab Page